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ABSTRAK
Tujuan: mempelajari peran faktor risiko klinis, penanda fungsi vasodilatasi, respons inflamasi, dan 
aterosklerosis dalam memprediksi penyembuhan luka kaki diabetik. Metode: studi kohort dilakukan sejak 
Februari – Oktober 2010 terhadap 40 subyek penelitian dengan ulkus diabetik akut di ruang rawat inap RSUPN 
Dr. Cipto Mangunkusumo, Jakarta, Indonesia. Pada setiap subyek, dilakukan minimal dua kali pengukuran 
variabel, yaitu pada fase inflamasi dan proliferasi. Variabel yang diteliti berupa karakteristik klinis, pemeriksaan 
darah perifer lengkap (DPL) dan hitung jenis, HbA1c, ureum, kreatinin, profil lipid, glukosa darah puasa 
(GDP), penanda disfungsi endotel (asymmetric dimethylarginine/ADMA, endothelin-1/ET-1, dan flow-mediated 
dilation/FMD arteri brakialis), dan penanda kalsifikasi vaskular (osteoprotegerin/OPG). Hasil: waktu rerata 
tercapainya jaringan granulasi 50% pada penelitian ini adalah 21 hari. Terdapat sembilan faktor yang berperan 
dalam pembentukan 50% jaringan granulasi, yaitu riwayat DM pada keluarga, riwayat luka, luas luka, lama 
luka, pemakaian kaptopril dan simvastatin, konsentrasi ADMA, ET-1, dan OPG. Terdapat tiga dari sembilan 
faktor yang secara signifikan berkorelasi terhadap penyembuhan luka, yaitu luas luka, konsentrasi OPG, dan 
pemakaian simvastatin. Kesimpulan: pada ulkus diabetik akut, luas luka dan konsentrasi OPG memiliki korelasi 
positif terhadap penyembuhan luka, sementara pemakaian simvastatin memiliki korelasi negatif terhadap 
penyembuhan luka.
Kata kunci: ulkus diabetik, penyembuhan luka, disfungsi endotel, kalsifikasi vaskular.
ABSTRACT
Aim: to evaluate the role of clinical characteristics, functional markers of vasodilation, inflammatory 
response, and atherosclerosis in predicting wound healing in diabetic foot ulcer. Methods: a cohort study 
(February – October 2010) was conducted from 40 subjects with acute diabetic foot ulcer at clinical ward of 
Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, Indonesia. Each subject underwent at 
least two variable measurements, i.e. during inflammatory phase and proliferation phase. The studied variables 
were clinical characteristics, complete peripheral blood count (CBC) and differential count, levels of HbA1c, 
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ureum, creatinine, lipid profile, fasting blood glucose (FBG), marker of endothelial dysfunction (asymmetric 
dimethylarginine/ADMA, endothelin-1/ET-1, and flow-mediated dilation/FMD of brachial artery), and marker 
of vascular calcification (osteoprotegerin/OPG). Results: median of time achieving 50% granulation tissue in 
our study was 21 days. There were nine factors that contribute in the development of 50% granulation tissue, 
i.e. family history of diabetes mellitus (DM), previous history of wound, wound area, duration of existing wound, 
captopril and simvastatin medications, levels of ADMA, ET-1, and OPG. There were three out of the nine factors 
that significantly correlated with wound healing, i.e. wound area, OPG levels, and simvastatin medications.
Conclusion: in acute diabetic foot ulcers, wound area and OPG levels had positive correlation with wound 
healing, whereas simvastatin medications had negative correlation with wound healing.
Keywords: diabetic ulcer, wound healing, endothelial dysfunction, vascular calcification.
INTRODUCTION
Diabetic foot is one of the most feared 
chronic complication of diabetes mellitus (DM). 
The mortality rate of diabetic foot complication 
was reported to remain high even after life-saving 
amputation procedure.1 Several previous studies 
held in Indonesia had documented the rate to 
be in range of 17-32%, while the proportion 
of amputation was 15-30%. One-year survival 
following amputation can be as high as 14.8%, 
but the rate dramatically increases up to 37% 
in the next three years. Though amputation 
was thought to be an effective treatment of 
complicated diabetic foot ulcer, preexisting 
clinical background does affect the final outcome 
of the subjects.2
Time prediction model has already been 
developed for wound healing process in 
diabetic ulcer. Longer healing time was found 
in subjects characterized by old wound that 
existed for longer than 2 months, involving 
area of more than 2 cm2, and penetrating deeper 
than subcutaneous layer in extent.3 Zimny et 
al.4 developed a formula to predict healing 
time for neuropathic ulcer in subjects with 
type 1 and type 2 DM who had neuropathic 
ulcer without peripheral arterial disease (PAD). 
Other prospective studies constructed similar 
prediction rules, but no additional indicators 
were included except wound characteristics and 
the dynamics of the healing process.5
The underlying mechanisms leading to 
the impairment in diabetic wound healing are 
still not fully understood and hence requires 
more intense investigation. Several known 
factors, such as endothelial dysfunction, 
inflammation and immunological responses, 
as well as atherogenesis with its subsequent 
vascular calcification, are responsible for 
this phenomenon observed in many diabetic 
wounds. It was reported earlier that increase in 
endothelin-1 (ET-1) and decrease in nitric oxide 
(NO) production were found in many diabetic 
patients, while osteoprotegerin (OPG) plays a 
significant role in atherogenesis of smaller and 
larger vessels.6-8 Increased OPG expression in 
type 2 DM has been reported to be correlated 
with micro- and macroangiopathy as well 
as impaired endothelium-dependent arterial 
vasodilation.9
While previous wound studies were 
conducted mainly on animals, current knowledge 
still needs further information about the role 
of clinical characteristics, markers of vascular 
tone regulation, and vascular calcification as the 
predictor of final outcome. It is proposed that 
there are differences in vasodilatory function 
and the level and expression of angiogenic 
factors in inflammatory phase compared to the 
proliferative phase among acute diabetic foot 
ulcer patients. This study aims to study the role 
of clinical characteristics, functional markers 
of vasodilation, inflammatory response, and 
atherosclerosis in predicting wound healing in 
diabetic foot ulcer.
METHODS
An observational cohort study was conducted 
in February-October 2010 among  inpatients 
admitted for acute foot ulcer and type 2 DM in Dr. 
Cipto Mangunkusumo National Central General 
Hospital, Jakarta, Indonesia. Out of 40 subjects, 
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twenty five subjects successfully completed the 
study which met the criteria of minimum sample 
size. Fifteen subjects were unable to complete 
the study and excluded from further analysis – 4 
subjects underwent amputation, 5 patients died, 
and 4 patients dropped out. There were missing 
data from 2 patients in the proliferative phase.
Patients with ulcer or gangrene who developed 
sepsis or critical limb ischemia (CLI) were 
excluded from the study as it was not possible 
to perform complete observation and due to 
other confounding inflammatory factors. CLI 
was diagnosed based on physical findings and/or 
ankle-brachial index (ABI) result less than 0.8. 
Wound severity evaluation was assessed based on 
the Modified Texas Criteria (Table 1).
The manuscript had been fully approved by 
team of ethics at Faculty of Medicine, Universitas 
Indonesia with the ethical number of 374/PT02.
FK/ETIK/2009 and it had also been approved 
by the Director of Dr. Cipto Mangunkusumo 
National Central General Hospital. All subjects 
were first asked to confirm their participation in 
this study by signing on the provided informed 
consent in correspondence with International 
Conference on Harmonization, which included 
prior explanation about study risks.10
There were at least two measurements 
conducted in association with the stages 
of healing process in which the respective 
subject diagnosed to, i.e. inflammatory phase 
and proliferative phase. Information includes 
complete peripheral peripheral blood count 
(CBC) and differential count, HbA1c, ureum, 
creatinine, lipid profile, fasting blood glucose 
(FBG), asymmetric dimethylarginine (ADMA), 
ET-1, OPG, and flow-mediated dilatation 
(FMD) of brachial artery, were measured in 
both phases. The same measurements were 
carried out at proliferative phase or at the 
fourth week of wound care. Proliferative phase 
was characterized by a tendency of reduced 
leukocyte count or the presence of granulation 
tissue in >50% of wound area or the wound 
demonstrated to be in the proliferative phase 
based on histopathological examination and no 
sign of infection or inflammation observed. To 
measure the granulation area, transparant film 
was manually placed over the wound and the 
outline was traced with a permanent marker. 
The film was then put onto metric grids and the 
area was determined by counting the number of 
square it covered. All subjects received standard 
treatment and care for acute diabetic ulcer in 
Cipto Mangunkusumo Hospital.11
Table 1. The degree of wound severity based on Modified Texas Criteria10
Stage
Grade
0 1 2 3
A
No ulcer or post 
ulcer, intact skin or 
bone
Superficial ulcer, but it 
does not penetrate to 
tendon or joint capsule
The wound 
penetrates to 
tendon or joint 
capsule
The wound 
penetrates to bone/ 
joint
B Infection 1 Infection of skin and subcutaneous tissue 
2 Erythema of >2 cm or infection involving subcutaneous structure, signs of SIRS (-)
3 Infection with systemic manifestations: fever, leukocytosis, shift to the left, metabolic instability, 
hypotension, azotemia  





B1 Infection of skin and subcutaneous tissue 
B2 Erythema of >2 cm or infection involving subcutaneous structure, signs of SIRS (-)
B3 Infection with systemic manifestation: fever, leukocytosis, shift to the left, metabolic instability, 
hypotension, azotemia 
C1 There are signs and symptoms of PAD, but none of CLI 
C2 CLI
SIRS: systemic inflammatory response syndrome; PAD: peripheral arterial disease; CLI: critical limb ischemia
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FMD measurement was carried out by 
B-mode Doppler Ultrasonography (US) MyLab 
30CV, Esaote. Brachial artery scanning was 
performed at rest and hyperemia conditions, 
the latter in which was induced by inflating and 
deflating the sphygmomanometer manset until 
the pressure raised up to 50 mmHg above the 
patient’s systolic. Luminal diameter was defined 
as the largest diameter calculated between two 
adventitia layers of the artery. We used the 
following equation to assess the endothelial 
function: [Dmax-D]/D; Dmax referred to the 
hyperemic diameter, while D referred to diameter 
during rest. The result was then considered to be 
normal if there was more than 10% change in the 
luminal diameter before and after compression. 
Evaluation of vasodilation and vascular 
calcification markers were carried out by 
enzyme-linked immunosorbent assay (ELISA) 
using the following kits: Endotelin-1 (IBL 
International), ADMA (DLD Diagnostic GmBH), 
and OPG (IDS Lucron Bioproduct) at Integrated 
Laboratory of Immunoendocrinology, Faculty of 
Medicine, Universitas Indonesia.
Statistical Analysis
Data cleaning was meant to replace any 
missing values with the one predicted by linear 
regression model. Any new variables gained 
from univariate analysis was then adjusted for 
further analysis. Based on the results of univariate 
analysis, some variables were then classified into 
new variables with adjusted categories for further 
analysis. Bivariate analysis was carried out to 
observe the correlation between each independent 
variable and the output, i.e. wound healing.12
Multivariate analysis used linear regression 
for dependent variables, which were numerical 
data. Variables of interaction were included in 
the multivariate model when the p value was less 
than 0.25. Analysis on survival was performed to 
evaluate the time needed for the development of 
50% granulation tissue as a parameter of healing 
and factors of independent variables associated 
with the incidence of healing. Analysis on survival 
was performed using Kaplan-Meier survival curve, 
which was followed by Cox proportional hazard 
regression when we found there was more than 
one independent variable (covariate) showing 
significant correlation with the incidence of healing.
Table 2. Clinical characteristics of subjects
Variables Values
Sex, n (%)
 - Female 22 (55.00)
 - Male 18 (45.00)
Age (years) 56.0 (49.25 – 59.00)
History of CAD, n (%)
 - Yes 11 (28.00)
 - No 29 (72.00)
History of stroke, n (%)
 - Yes 3 (8.00)
 - No 37 (92.00)
Body mass index (kg/m2) 22.35 (18.54 – 25.16)
Systolic blood pressure (mmHg) 120.00  (120.00 – 130.00)
Diastolic blood pressure 
(mmHg) 80.00 (70.00 – 80.00)







LDL cholesterol (mg/dL) 67.00 (50.25 – 83.75)
HDL cholesterol (mg/dL) 19.50 (14.00 – 29.00)
Fasting blood glucose (mg/dL)
216.50  
(130.25 – 291.50)
HbA1c (%) 9.85 (8.40 – 11.38)
Period of time of having DM 
(years) 4.00 (1.25 – 9.75)
Family history of DM, n (%)
 - Yes 20 (50.00)
 - No 20 (50.00)
History of using DM medication before having wound, 
n (%)
 - OAD 24 (60.00)
 - Insulin 4 (10.00)
 - OAD and insulin 5 (12.00)
 - No medications 7 (18.00)
Treatment using captopril during wound care, n (%)
 - Yes 25 (63.00)
 - No 15 (37.00)
Treatment using simvastatin during wound care, n (%)
 - Yes 12 (30.00)
 - No 28 (70.00)
Ankle Brachial Index 1.02 (0.95 – 1.11)
Subjective symptoms about foot 
 - Tingling 22 (55.00)
 - Numbness 24 (60.00)
 - Intermittent claudication 8 (20.00)
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RESULTS
Clinical characteristics of the subjects in 
this study can be seen on Table 2. About 55% 
subjects were female with the median age of 56 
years (49.25 – 59). The median of BMI was 22.35 
which is in overweight range referring to Asian 
BMI. Majority of the subjects had no history 
of coronary artery disease (CAD) and stroke. 
Median of HbA1c levels was 9.85 (8.4 – 9.38). 
Although the median of lipid profile levels was 
in normal range, we found as many as 70% of 
subjects with statin medications.
Wound Characteristics
Wound characteristics of the subjects were 
varied and can be seen on Table 3. Most of the 
wound were as deep as muscle (35%) and bone 
(35%), with sign of local inflammation. Analysis 
using Kaplan Meier survival curve (Figure 1) 
revealed that there were as much as 81% subjects 
had not achieved 50% granulation tissue on 
the 14-day. The median of time achieving 50% 
granulation tissue in this study was 21 days (95% 
CI, 18.4 – 23.6). There were 3 out of 40 subjects 
dropped out before the earliest healing time (10 
days). Longest treatment care until full recovery 
was 54 days.
Marker of Endothelial Dysfunction and 
Vascular Calcification
Marker of endothelial dysfunction (FMD, 
ADMA, and ET-1) and vascular calcification 
(OPG) in the inflammatory and proliferative phase 
were compared (Table 4). There was significant 
difference of OPG levels as the vascular 
calcification marker between inflammatory and 
proliferative phase. However, there were no 
significant differences of endothelial dysfunction 
markers between the two phases.
Bivariate and Multivariate Analysis
According to the bivariate analysis (Table 
5), there were some factors which significantly 
correlated with wound healing (p<0.25), such 
as wound area, captopril and simvastatin 
medications, total cholesterol, fasting blood 
glucose, levels of ADMA, and OPG.
Multivariate analysis using Cox regression 
method was subsequently performed to the 
significant factors as well as clinical and 
laboratory characteristics which were considered 
important i.e. family history of DM, previous 
history of wound, and ET-1 (Table 6). There were 
Table 3. Wound characteristics
Variables Values
Wound depth, n (%)
 - Subdermal 1 (2.00)
 - Muscle 14 (35.00)
 - Tendon 11 (28.00)
 - Bone 14 (35.00)
Infection, n (%)
 - Yes 38 (95.00)
 - No 2 (5.00)
History of amputation, n (%)
 - Yes 3 (8.00)
 - No 37 (92.00)
History of previous wound, n (%)
 - Yes 17 (43.00)
 - No 23 (57.00)
History of having wound (days) 14.00 (7.00 -21.00)
Median of wound area (cm2) 47.30 (21.88 – 71.63)
Texas Wound Classification, n (%)
 - A0 0 (0.00)
 - A1 12 (30.00)
 - A2 14 (35.00)
 - A3 14 (35.00)
 - B1 0 (0.00)
 - B2 38 (95.00)
 - C1 12 (30.00)
 - D 11 (28.00)
Figure 1. Survival curve of Kaplan Meier
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Table 4. Marker of endothelial dysfunction and vascular calcification in the inflammatory and proliferative phase
Variables Inflammatory Phase Proliferative Phase p value
FMD (%) 2.97 (-2.63 – 5.58) 5.07 (0.80 – 8.62) 0.712
ADMA (mmol/L) 0.73 (0.61 – 1.07) 0.77 (0.64 – 1.07) 0.221
ET-1 (pg/mL) 4.38 (3.61 – 7.81) 4.40 (3.48 – 7.52) 0.757
OPG (pg/mL) 240.80 (185.12 – 314.61) 342.60 (246.60 – 387.10) 0.009
*Normal value: FMD >10%, ADMA 0.4-0.75 mmol/L, ET-1 0.3-0.9 pg/mL, OPG 37 pg/mL
Table 5. Bivariate analysis of factors related to wound healing




Length of diabetes from diagnosis -0.005 0.995 0.945 1.042 0.837
Family history of DM 0.191 1.210 0.576 2.540 0.614*
Previous history of wound 0.187 1.205 0.574 2.529 0.621*
Wound area 0.008 1.008 0.999 1.017 0.076
History of amputation 0.236 1.266 0.377 4.254 0.703
Infection -0.441 0.663 0.153 2.863 0.582
History of CAD 0.186 1.204 0.534 2.717 0.655
Treatment using captopril during wound care -0.708 0.492 0.217 1.116 0.090
Treatment using simvastatin during wound care -0.508 0.502 0.265 1.366 0.225
Body mass index 0.035 1.036 0.940 1.142 0.476
Systolic blood pressure 0.010 1.010 0.983 1.037 0.487
Diastolic blood pressure 0.010 1.010 0.965 1.057 0.659
ABI -1.052 0.349 0.018 6.810 0.488
FMD -0.004 0.996 0.945 1.050 0.889
Total cholesterol 0.008 1.008 0.994 1.022 0.245
Total triglyceride 0.000 1.000 0.994 1.007 0.958
LDL cholesterol 0.008 1.008 0.992 1.025 0.302
HDL cholesterol 0.015 1.015 0.976 1.056 0.456
Fasting blood glucose -0.002 0.998 0.996 1.001 0.143
HbA1c -0.032 0.969 0.813 1.155 0.723
ADMA 1.338 3.813 1.116 13.023 0.033
ET-1 -0.002 0.998 0.868 1.146 0.975
Angiogenin 0.000 1.000 1.000 1.000 0.990
OPG 0.003 1.003 0.999 1.008 0.148
*variables were analyzed with Cox proportional hazard
three out of the nine factors that significantly 
correlated with wound healing, i.e. wound area, 
OPG levels, and simvastatin medications.
DISCUSSION
This study constitutes as the first observational 
cohort study aims to observe factors affecting the 
wound healing process which is commonly found 
in type 2 DM patients.
Median duration of DM among subjects 
was 4 years (1.25 – 9.75) with 60% subjects had 
already been using OAD for their medication 
before having wound, followed by 10% using 
insulin, and 12% using both OAD and insulin. 
Median of HbA1c levels was 9.85 (8.40–11.38)%, 
which showed that subjects had poor glycemic 
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control. Based on lipid profile, all subjects were 
categorized as hypocholesterolemia with low 
levels of low and high density lipoprotein (LDL 
and HDL). Some studies show that cholesterol 
levels (total cholesterol, LDL, and HDL are 
affected by inflammatory cytokines that may 
cause reduced synthesis or increased catabolism 
of cholesterol.13,14
The development of diabetic foot as a 
complication was quite too early considering 
the median duration of DM among subjects was 
4 years. The median value of blood pressure 
was in pre-hypertension category which was 
consistent with most subjects receiving captopril. 
About 20% subjects were assumed to have PAD 
since they had signs of intermittent claudication 
regardless of the median value of ankle brachial 
index (ABI) falling within normal range. Normal 
ABI value indicating the undisrupted vascular 
integrity cannot exclude the presence of previous 
thromboemboli. The presence of vasodilation 
disorder in a relatively well macrovascular 
condition can explain the impaired healing 
process among subjects of our study.
About 60% of the subjects had numbness on 
their feet, 55% tingling, and 20% intermittent 
claudication, which showed neuropathy 
symptoms of the subjects.
Most of the wound were deeper than 
subdermal and coexisted with infection. Most of 
the subjects had no history of amputation. The 
median of wound duration was 14 days, which 
showed late treatment of the wound. Median of 
wound area was 47.30 cm2.
There were 27 out of 40 subjects which 
followed the study until >50% granulation tissue 
(proliferation phase) achieved. Kaplan-Meier 
survival analysis showed the median of time 
achieving 50% granulation tissue was 21 days. 
Time achieving proliferation phase in normal 
people begins on day-4 and ends at day-21 
after injury.15 In this study, there was still 50% 
granulation tissue formation at day-21 which 
indicates that people with type 2 DM will have 
a longer duration of wound healing compared 
with normal people.
Marker of Endothelial Dysfunction in 
Inflammation and Proliferation Phase
In this study, marker of endothelial 
dysfunction was determined by FMD, ADMA, 
and ET-1 levels.
In proliferation phase, the metabolic disorder 
and cardiovascular risk factor are assumed to 
be improved thus produce better vasodilation. 
In this study, FMD median value was higher in 
proliferation phase than in inflammation phase, 
eventhough the increase was not statistically 
significant (p=0.712). However, the median FMD 
in proliferation phase was still below normal 
(<10%), showing despite acute metabolic factor 
improvement, endothelial dysfunction had not 
improved yet because of chronic inflammation 
affecting vascular elasticity. Type 2 DM subjects 
with inflammation phase of diabetic ulcer had 
FMD median of 2.97% (-2.63 – 5.58) which was 
very different with the study by Pribadi.16 finding 
Table 6. Multivariate analysis of various clinical and laboratory risk factors on wound healing
Variables B Hazard Ratio Standard error p value 95% CI
Family history of DM 0.908 2.480 0.615 0.139 0.744-8.273
Previous history of wound -0.584 0.558 0.561 0.298 0.186-1.675
Wound area 0.014 1.014 0.006 0.027 1.002-1.027
Duration of existing wound (days) -0.038 0.963 0.024 0.121 0.918-1.010
ADMA (µmol/L) 1.530 4.617 0.872 0.080 0.835-25.521
ET-1 (pg/mL) 0.119 1.126 0.095 0.214 0.934-1.358
OPG (pg/mL) 0.009 1.009 0.003 0.003 1.003-1.015
Using captopril -0.685 0.504 0.478 0.152 0.197-1.288
Using simvastatin -1.158 0.314 0.557 0.038 0.105-0.936
Overall chi square= 20.9, p=0.022; DM: diabetes mellitus; ADMA: asymmetric dimethylarginine; ET-1: endothelin-1; 
OPG: osteoprotegerin
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7.46% as FMD mean in non-fasting healthy men 
or by Elliana.17 finding 11.09% as FMD mean 
in prediabetes women. FMD measurement on 
those diabetic patients could not only show 
the change in local vascular function, but also 
systemic vascular function. In this study, FMD 
was measured on brachialis artery and associated 
with peripheral vascular disturbance.
Vasodilation function is important because 
vasodilation and vasoconstriction are dynamic 
mechanism of which are needed for optimal 
wound healing. Some studies have reported 
failure of vasodilation and vasoconstriction on 
diabetic patients can be detected through FMD 
measurement.18,19
Vasodilation and vasoconstriction balance 
on systemic vasculature are shown by two main 
components, i.e. NO and ET-1. However, NO is 
difficult to be measured due to its very short half 
life. Therefore, ADMA as another metabolite in 
vasodilation can be used after NO.
In our study, ADMA levels in proliferation 
phase was higher than inflammation phase. 
Increased ADMA was thought to be required for 
inhibition of NO as a physiological factor that 
is used against further inflammatory process in 
order to protect the endotelium.
Increased ADMA is equal to decreased NO 
as reported by Mahfouz et al.20 This study found 
the median of ADMA levels is 0.73 (0.61 – 1.07) 
mmol/L in inflammation phase, which is higher 
compared with the mean of ADMA levels by 
Elliana.17 in prediabetic women 0.65 (0.13) 
mmol/L or by Zoccali et al.21 in acute infection 
0.62 (0.23) mmol/L. An increase in ADMA levels 
is often found in diabetic patients,20 and can 
precede vascular abnormalities in abscence of 
hypertension and dyslipidemia.22 Hyperglycemia 
can increase ADMA levels through some 
mechanisms, i.e. polyol pathway activation 
that can decrease biosynthesis of NO, damage 
of DDAH as ADMA degradation enzyme, and 
increase arginine methyltransferase expression 
as ADMA synthesizer.20,23,24
In our study, we found a higher degree 
of wound healing, which is consistent with 
increased ADMA levels. Our findings were 
different from Gurdol et al.25, i.e. subjects with 
worse wound healing actually had higher ADMA 
levels. The difference may be caused by limited 
number of sample in our study and therefore, 
further study is necessary to confirm the role of 
ADMA to determine the prognosis of wound 
healing of DM ulcer. Furthermore, no study has 
been reported about the direct effect of ADMA 
on wound healing.
Other factor which constitutes in FMD 
decrement is ET-1. The high level of ET-1 
at initial phase can induce an increased NO 
production, which contributes in vasodilation 
process; the mechanism is also considered that it 
may affect the degree of wound healing. ET-1 is 
generally known as a vasoconstrictor substance. 
But then, some studies demonstrate that it has 
a role in wound healing and tissue repair. ET-1 
has mitogenic activity on some types of cells, 
such as smooth muscle cells and fibroblasts. 
It affects the composition of extracellular 
matrix by inducing the synthesis of collagen I 
and III through ETA and ETB receptors. ET-1 
has also been reported to have an effect of 
increasing contractility of normal fibroblasts, 
which is required for wound closure and dermal 
reconstitution.26 Increase in ET-1 level has 
made the vasodilation and vasoconstriction 
balance prone to vasoconstriction. ET-1 levels in 
inflammation and proliferation phase was above 
normal. This study used subjects who at most 
had infection and impaired perfusion stimulation 
in inflammation phase. Once the inflammatory 
phase completed, it was assumed that both 
infection and impaired perfusion improved in 
proliferation phase. This study found that the 
average ratio of ET-1 in both phases ran in 
accordance with the processes described above. 
The value was higher than normal subjects in 
Lilyasari et al.27 which showed ET-1 levels 0.88 
(0.77 – 1.07) pg/mL. However, increased FMD 
value, ADMA, dan ET-1 levels in proliferation 
phase did not statistically significant. Correction 
of acute inflammatory conditions would not 
correct all metabolic and inflammatory factors 
because of ongoing chronic inflammatory 
process in DM.
Comparison of vasodilation function in this 
study was to show the importance of correction 
of acute inflammation as the basic distinction 
between inflammation and proliferation phase, 
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in association with vascular change. However, 
chronic inflammation in diabetic patients as a 
risk factor prior to the development of wound 
needs to be considered.
Marker of  Vascular  Calci f icat ion in 
Inflammation and Proliferation Phase
OPG levels increased seven-fold above 
normal value in inflammation phase. Besides 
basically diabetic patient has already increased 
levels of OPG, inflammatory process in subjects 
who participated in this study was believed 
to be the cause of increased OPG. High OPG 
levels in DM is associated with the presence of 
inflammation related to various inflammatory 
cytokines, such as IL-6 and TNF-a.28,29 Chronic 
inflammation in subjects was not only observed 
in the vasodilation function, but also the 
character of atherosclerosis and vascular 
calcification, assessed by OPG levels. Several 
studies indicate that in DM population, OPG 
levels were lower by insulin and simvastatin 
therapy of which the mechanism was thought 
through anti-inflammatory effects. In this study, 
OPG levels remained significantly increased in 
proliferation phase, suggesting the process of 
angiogenesis.
Factors Related to Wound Healing
Earlier studies proposed their own prediction 
model of time for wound healing, but only put 
concerns of the wound closure at the beginning. 
Sheehan et al.5 found that percent change in 
the area of ulcer after 4 weeks of observation 
can predict healing at 12 weeks, which can be 
used for early identification of standard care 
response and the need for additional treatment. 
Besides, Lavery et al.30 found that percentage of 
wound area reduction at 1 week of observation 
can predict healing at 16 weeks. On the other 
hand, Zimny et al.4 confirmed an equation that 
can reliably predict healing time in neuropathic 
foot ulcers.
In addition to wound area, this study tried 
to look up other factors affecting wound healing 
process, such as family history of DM, previous 
history of wound, duration of existing wound, 
medication history (including angiotensin-
converting enzyme inhibitors and statins), serum 
levels of ADMA, ET-1, and OPG.
Based on multivariate analysis, there were 3 
out of 9 factors that had significant role in wound 
healing. Greater wound area, higher levels of 
OPG, and absence of simvastatin medications 
increased wound healing. On the contrary, 
subjects with previous history of wound, longer 
duration of wound, as well as history of captopril 
and simvastatin medications showed decreased 
healing process.
Subjects with history of DM in the family, 
larger baseline wound area, high baseline 
ADMA, ET-1, and OPG levels will have impact 
to the high degree of healing. The effect of 
history of DM in the family on higher degree of 
healing is assumed caused by earlier and more 
intensive care when the wound develops in 
subjects who had family history of DM compared 
to those without.
It was assumed that subjects with previous 
history of wound had worse neuropathy and 
vascular disorder as well as metabolic control 
compared to subjects with no previous history 
of wound. Furthermore, previous history of 
wound increased the risk of recurrent ulcer and 
amputation.32 Previous wound history also serves 
as a predictor for recurrent ulcer and higher the 
amputation risk of these subjects. Glycemic 
control was not significantly related to the 
healing process due to its long term effect in the 
otherwise acute process of ulcer in this study.
Subjects with longer duration of wound prior 
to treatment were  estimated to  have more severe 
infection and metabolic disorder since they 
relatively had a delay in receiving proper wound 
care. This finding is consistent with the study 
by Ince et al.33 which showed lower degree of 
healing in subjects having long-standing wound. 
The longer the wound exists, the larger the area 
it occupies, and the higher the risk of developing 
secondary infection as well.
Regarding the correlation between high 
levels of cytokines such as ADMA, ET-1, and 
OPG in inflammatory phase and the degree of 
healing, it has been shown that the higher the 
level of those three cytokines, the higher the 
degree of wound healing.
OPG has been so far considered as a marker 
of vascular and bone calcification and it may 
be involved in the development of various 
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microvascular complications of DM. There has 
been no study explaining the correlation between 
wound healing of DM patients and OPG levels. 
Malyankar et al.31 found that OPG protected 
endothelial cells from apoptosis and it had a role 
in angiogenesis in rats. Hence, it may explain the 
role of OPG in wound healing.
This study demonstrates that the medication 
history of captopril and simvastatin has a 
negative correlation with wound healing. 
Simvastatin is an LDL-lowering agent, whereas 
LDL stimulate fibroblast in human skin through 
activation of p38 mitogen-activated protein 
kinases (MAPKs), followed by interleukin-8 (IL-
8) production that will finally increase the wound 
healing capacity of fibroblasts.34 The presence of 
LDL has actually provided assistance in wound 
healing, and therefore lowering its level may 
impair wound healing.
Various results about the impact of captopril 
medication on wound healing have been reported. 
A study by Torgal et al.35 in experimental animal 
showed that captopril and enalapril significantly 
increased the development of granulation tissue 
and hydroxyproline. On the other hand, Ilhan 
et al.36 reported contrary results, i.e. high-dose 
lisinopril reduced hydroxyproline level, collagen 
deposition, and intestinal epithelization in 
experimental animals. However, our study was 
not aimed to show the direct effect of captopril 
or simvastatin on wound healing. Therefore, the 
results of our study regarding both issues should 
be interpreted wisely. Subjects who had captopril 
or simvastatin in our study were those with 
history of hypertension or dyslipidemia, in which 
both treatments were given to maintain controlled 
blood pressure and lipid profile. Hypertension 
and dyslipidemia are comorbidity besides DM 
that may affect wound healing through the 
process of endothelial dysfunction. Moreover, 
the presence of comorbidities other than DM 
also increases the risk of macroangiopathy that 
may also affect wound healing.37-39
The limitation of this study is the total 
number of subjects is less than the minimum 
sample size, thus causing low power of the study 
(P=50%) and higher type 2 error as well as lower 
possibility to find association between the studied 
variables. Besides, many subjects could not 
complete the whole study. Due to limited funds, 
marker of endothelial dysfunction and vascular 
calcification were only done in subjects which 
completed the study. Other limitation is there 
was no comparisons between type 2 DM and 
normal population.
CONCLUSION
In acute diabetic foot ulcers, wound area and 
OPG levels had positive correlation with wound 
healing, whereas simvastatin medications had 
negative correlation with wound healing.
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